Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Next Previous
X
Search
Trial Profile

Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sufentanil (Primary)
  • Indications Postoperative pain
  • Focus Registrational; Therapeutic Use
  • Sponsors AcelRx Pharmaceuticals; Talphera

    • Most Recent Events

    • 09 Jan 2024 According to Talphera media release, AcelRx Pharmaceuticals changed its name to Talphera, Inc.
    • 02 Nov 2018 According to an AcelRx Pharmaceuticals media release, U.S. Food and Drug Administration has approved DSUVIA for the management of acute pain in adults that is severe enough to require an opioid analgesic in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments.
    • 15 Oct 2018 According to an AcelRx Pharmaceuticals media release, data will be presented at the American Society of Anesthesiologists (ASA).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top